A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma was written by Lee, Hans C.;Feng, Lei;Oriabure, Onyeka;Graham, Vivian;Chen, Wendy;Badillo, Maria;Lu, Rebecca;Lee, Hun J.;Jain, Preetesh;Manasanch, Elisabet E.;Orlowski, Robert Z.;Wang, Michael L.. And the article was included in American Journal of Hematology in 2021.Recommanded Product: 16506-27-7 The following contents are mentioned in the article:
The incorporation of novel agents including immunomodulatory drugs(IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs) to myeloma treatment regimens have led to substantial gains in overall survival in patients with multiple myeloma over the last 10-15 years. However, alkylating agents remain an important option in the myeloma therapeutic armamentarium, and their use in combination with novel agents have shown to be an effective treatment strategy for both newly diagnosed and relapsed and/or refractory myeloma patients. The primary endpoint of the study was to determine the MTD of carfilzomib, bendamustine and dexamethasone with dose-limiting toxicities (DLTs) assessed during the cycle one (28-day) DLT-evaluable period. In summary, we establish the MTD of the combination of carfilzomib, bendamustine, and dexamethasone in RRMM and demonstrate its encouraging preliminary efficacy in this phase one study. These data suggest that carfilzomib in combination with the alkylating agent bendamustine may be a useful and relevant treatment option in this patient population. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 16506-27-7).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Recommanded Product: 16506-27-7
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem